Legal & General Group
MNPR icon

Legal & General Group’s Monopar Therapeutics MNPR Stock Holding History

Legal & General Group’s Portfolio MNPR Stock Details MNPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$22.4K Sell
408
-71
-15% -$4.29K ﹤0.01% 2926
2025
Q4 		$31.3K Buy
479
+102
+27% +$8.33K ﹤0.01% 2857
2025
Q3 		$30.8K Sell
377
-76
-17% -$3.4K ﹤0.01% 2880
2025
Q2 		$16K Buy
+453
New +$16.5K ﹤0.01% 3103

Other funds holding MNPR

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Legal & General Group's MNPR Position: Q1 2026 in Review

Legal & General Group reduced its Monopar Therapeutics (MNPR) stake by 15% in Q1 2026, selling an estimated $4.29K and leaving 408 shares worth $22.4K. The position accounts for ﹤0.01% of the portfolio, ranked #2926.

Legal & General Group first reported a position in MNPR in Q2 2025 and has held it in 4 quarters since. The position peaked at $31.3K in Q4 2025. 82 funds tracked by Wall St. Rank hold MNPR as of Q1 2026.

  • Legal & General Group held 408 shares of Monopar Therapeutics worth $22.4K as of Q1 2026.
  • Legal & General Group sold 71 Monopar Therapeutics shares in Q1 2026, an estimated $4.29K.
  • Monopar Therapeutics made up ﹤0.01% of Legal & General Group's portfolio in Q1 2026, its #2926 holding.
  • Legal & General Group first reported a position in Monopar Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • Legal & General Group's Monopar Therapeutics position peaked at $31.3K in Q4 2025.
  • 82 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q1 2026.

Based on Legal & General Group's 13F filing for Q1 2026, filed 8 May 2026.